BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20931131)

  • 1. Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology.
    Robers MB; Loh C; Carlson CB; Yang H; Frey EA; Hermanson SB; Bi K
    Mol Biosyst; 2011 Jan; 7(1):59-66. PubMed ID: 20931131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.
    Solomon JM; Pasupuleti R; Xu L; McDonagh T; Curtis R; DiStefano PS; Huber LJ
    Mol Cell Biol; 2006 Jan; 26(1):28-38. PubMed ID: 16354677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIPK2 modulates p53 activity towards pro-apoptotic transcription.
    Puca R; Nardinocchi L; Sacchi A; Rechavi G; Givol D; D'Orazi G
    Mol Cancer; 2009 Oct; 8():85. PubMed ID: 19828042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 deacetylation by SIRT1 decreases during protein kinase CKII downregulation-mediated cellular senescence.
    Jang SY; Kim SY; Bae YS
    FEBS Lett; 2011 Nov; 585(21):3360-6. PubMed ID: 21968188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deacetylation of p53 after nerve growth factor treatment in PC12 cells as a post-translational modification mechanism of neurotrophin-induced tumor suppressor activation.
    Vaghefi H; Neet KE
    Oncogene; 2004 Oct; 23(49):8078-87. PubMed ID: 15361854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis.
    Puca R; Nardinocchi L; Starace G; Rechavi G; Sacchi A; Givol D; D'Orazi G
    Free Radic Biol Med; 2010 May; 48(10):1338-46. PubMed ID: 20171273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.
    Terui T; Murakami K; Takimoto R; Takahashi M; Takada K; Murakami T; Minami S; Matsunaga T; Takayama T; Kato J; Niitsu Y
    Cancer Res; 2003 Dec; 63(24):8948-54. PubMed ID: 14695212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylation of Sirt2 by p300 attenuates its deacetylase activity.
    Han Y; Jin YH; Kim YJ; Kang BY; Choi HJ; Kim DW; Yeo CY; Lee KY
    Biochem Biophys Res Commun; 2008 Oct; 375(4):576-80. PubMed ID: 18722353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases.
    Kloster MM; Naderi EH; Haaland I; Gjertsen BT; Blomhoff HK; Naderi S
    Int J Oncol; 2013 May; 42(5):1815-21. PubMed ID: 23483263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TR-FRET cellular assays for interrogating posttranslational modifications of histone H3.
    Machleidt T; Robers MB; Hermanson SB; Dudek JM; Bi K
    J Biomol Screen; 2011 Dec; 16(10):1236-46. PubMed ID: 21972037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TR-FRET biochemical assays for detecting posttranslational modifications of p53.
    Dudek JM; Horton RA
    J Biomol Screen; 2010 Jun; 15(5):569-75. PubMed ID: 20400726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
    Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B
    Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice.
    Hu N; Long H; Zhao M; Yin H; Lu Q
    Scand J Rheumatol; 2009; 38(6):464-71. PubMed ID: 19922023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase activity in conjunction with E2F-1 and p53 regulates Apaf-1 expression in 661W cells and the retina.
    Wallace DM; Cotter TG
    J Neurosci Res; 2009 Mar; 87(4):887-905. PubMed ID: 18951482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT1 regulates HIV transcription via Tat deacetylation.
    Pagans S; Pedal A; North BJ; Kaehlcke K; Marshall BL; Dorr A; Hetzer-Egger C; Henklein P; Frye R; McBurney MW; Hruby H; Jung M; Verdin E; Ott M
    PLoS Biol; 2005 Feb; 3(2):e41. PubMed ID: 15719057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
    Kang J; Chen J; Shi Y; Jia J; Zhang Y
    Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.
    Wang H; Zhou W; Zheng Z; Zhang P; Tu B; He Q; Zhu WG
    DNA Repair (Amst); 2012 Feb; 11(2):146-56. PubMed ID: 22112863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
    Monte M; Simonatto M; Peche LY; Bublik DR; Gobessi S; Pierotti MA; Rodolfo M; Schneider C
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11160-5. PubMed ID: 16847267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirt1 attenuates camptothecin-induced apoptosis through caspase-3 pathway in porcine preadipocytes.
    Pang WJ; Xiong Y; Wang Y; Tong Q; Yang GS
    Exp Cell Res; 2013 Mar; 319(5):670-83. PubMed ID: 23313858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.